Sarah Short
Post-Doc
Last active: 10/13/2017

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage. Barrett CW, Reddy VK, Short SP, Motley AK, Lintel MK, Bradley AM, Freeman T, Vallance J, Ning W, Parang B, Poindexter SV, Fingleton B, Chen X, Washington MK, Wilson KT, Shroyer NF, Hill KE, Burk RF, Williams CS (2015) J Clin Invest 125(7): 2646-60
    › Primary publication · 26053663 (PubMed) · PMC4563672 (PubMed Central)
  2. The transcriptional corepressor MTGR1 regulates intestinal secretory lineage allocation. Parang B, Rosenblatt D, Williams AD, Washington MK, Revetta F, Short SP, Reddy VK, Hunt A, Shroyer NF, Engel ME, Hiebert SW, Williams CS (2015) FASEB J 29(3): 786-95
    › Primary publication · 25398765 (PubMed) · PMC4763883 (PubMed Central)
  3. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Ciombor KK, Feng Y, Benson AB, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, Amiri KI, Richmond A, Berlin J (2014) Invest New Drugs 32(5): 1017-27
    › Primary publication · 24890858 (PubMed) · PMC4171216 (PubMed Central)
  4. Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, Zhang B, Hunt AA, Fingleton BM, Carnahan RH, Engel ME, Chen X, Beauchamp RD, Wilson KT, Hiebert SW, Reynolds AB, Williams CS (2012) PLoS One 7(12): e51205
    › Primary publication · 23251453 (PubMed) · PMC3521008 (PubMed Central)
  5. RAF265 inhibits the growth of advanced human melanoma tumors. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A (2012) Clin Cancer Res 18(8): 2184-98
    › Primary publication · 22351689 (PubMed) · PMC3724517 (PubMed Central)
  6. Adenoma formation following limited ablation of p120-catenin in the mouse intestine. Smalley-Freed WG, Efimov A, Short SP, Jia P, Zhao Z, Washington MK, Robine S, Coffey RJ, Reynolds AB (2011) PLoS One 6(5): e19880
    › Primary publication · 21611205 (PubMed) · PMC3096651 (PubMed Central)
  7. Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Brantley-Sieders DM, Dunaway CM, Rao M, Short S, Hwang Y, Gao Y, Li D, Jiang A, Shyr Y, Wu JY, Chen J (2011) Cancer Res 71(3): 976-87
    › Primary publication · 21148069 (PubMed) · PMC3032824 (PubMed Central)
  8. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME (2011) Cancer Res 71(2): 603-13
    › Primary publication · 21123450 (PubMed) · PMC3140407 (PubMed Central)
  9. p120-catenin is essential for maintenance of barrier function and intestinal homeostasis in mice. Smalley-Freed WG, Efimov A, Burnett PE, Short SP, Davis MA, Gumucio DL, Washington MK, Coffey RJ, Reynolds AB (2010) J Clin Invest 120(6): 1824-35
    › Primary publication · 20484816 (PubMed) · PMC2877948 (PubMed Central)
  10. Short tail with skin lesion phenotype occurs in transgenic mice with keratin-14 promoter-directed expression of mutant CXCR2. Yu Y, Su Y, Opalenik SR, Sobolik-Delmaire T, Neel NF, Zaja-Milatovic S, Short ST, Sai J, Richmond A (2008) J Leukoc Biol 84(2): 406-19
    › Primary publication · 18505935 (PubMed) · PMC2493076 (PubMed Central)